• Selecting vector, linker, and radionuclide to maximize tumour specificity, retention, and therapeutic index
• Preclinical and manufacturing considerations to ensure scalability, consistency, and early risk reduction
• Achieving the optimal clinical target product profile to drive efficacy, safety, and competitive differentiation in the clinic

New Company for 2026